Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10362/175990| Título: | Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum |
| Autor: | Kavanagh, David Ardissino, Gianluigi Brocklebank, Vicky Bouwmeester, Romy N. Bagga, Arvind ter Heine, Rob Johnson, Sally Licht, Christoph Ma, Alison L.T. Noris, Marina Praga, Manuel Rondeau, Eric Sinha, Aditi Smith, Richard J.H. Sheerin, Neil S. Trimarchi, H. Wetzels, Jack F.M. Vivarelli, Marina Van de Kar, Nicole C.A.J. Greenbaum, Larry A. Lungu, Adrian Catalin Żurowska, Aleksandra Gerogianni, Alexandra Durkan, Anne Schijvens, Anne Lapeyraque, Anne Laure Java, Anuja Awan, Atif Covella, Bianca Dixon, Brad El Sissy, Carine Duinevel, Caroline Maville, Christine Turudic, Daniel Karpman, Diana Haffner, Dieter Trembecka-Dubel, Elżbieta Ozaltin, Fatih Emma, Francesco Schaefer, Franz Kang, Hee Gyung Trimarchi, Hernán Trujillo, Hernando Ulasi, Ifeoma Ekwueme, Alex Menne, Jan Laurence, Jeffrey Calado, Joaquim Hofer, Johannes Zuber, Julien |
| Palavras-chave: | acute kidney injury C5 complement hemolytic uremic syndrome thrombotic microangiopathy Nephrology |
| Data: | Dez-2024 |
| Resumo: | Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described. |
| Descrição: | Funding Information: D.K. has received advisory board payments from Idorsia, Novartis, Chemocentryx, Alexion, Samsung, Sobi, Gyroscope Therapeutics, Purespring and Apellis. G.A. has received honoraria from Alexion Pharmaceuticals, Alnylam, Roche Novartis and Sobi for giving lectures, and for participating in advisory boards. C.L. has received honoraria as advisor or speaker from Alexion, AstraZeneca Rare Disease, Apellis Pharmaceuticals, Inc., Novartis, and Pfizer Inc. M.N. has received honoraria from Alexion Pharmaceuticals and Sobi for giving lectures, and for participating in advisory boards, and she has received research grants from Omeros, Gemini, Novartis and BioCryst Pharmaceuticals. M.P. has received honoraria from Alexion, Novartis, Otsuka, GSK, Samsung and Sanofi for lectures and advisory boards. E.R. is a member of the scientific advisory board of the Global aHUS registry launched by Alexion Pharmaceuticals. He received fees from Alexion for travels, communications, and clinical studies. R.J.H.S. directs the Molecular Otolaryngology and Renal Research Laboratories, which provides genetic and complement activity testing for the thrombotic microangiopathies. He also serves as a consultant for Novartis and receives research support from the National Institutes of Health. N.S. has received honoraria for advisory boards and talks for Alexion Pharmaceuticals, Astra Zeneca, Novartis, Roche, Therakos. Trial committee involvement for Roche and Novartis. H.T. has received honoraria from Alexion, Alpine Astra-Zeneca, Bayer, Biosidus, BioCryst, BMS, Calliditas, Chinook, Dimerix, Genzyme, Glaxo-Smith Klyne, Novartis, Omeros, Roche, Sanofi, Takeda, Retrophin-Travere, Vera Therapeutics, Visterra-Otsuka M.V. provides consultancy or participated in sponsored clinical trials by Novartis, Roche, Apellis, Alexion, Travere, PureSpring, Chinook, Chemocentrix, Biocryst, has given sponsored lectures for Vifor, Travere, Roche, Novartis, Glaxo. N.C.A.J.vdK. has received consultancy fees from Roche Pharmaceuticals, Novartis, Samsung and Alexion and is (sub) investigator in the APL2-C3G trial, Apellis and APPEAR-C3G trail, Novartis.J.W. has received grants for clinical trials; honoraria scientific advisory committee from Alexion; HiBio; Novartis. Funding Information: The authors thank Monica Moorthy, Charu Malik, Paolo Zavalloni, Th\u00E9o Treppo, Charleigh Claire, and Ilaria Pastorino for organisational support of this forum. The authors would also like to thank Giedre Peseckyte, the forum medical writer. The ISN aHUS International forum was supported by Alexion AstraZeneca Rare Disease. The authors did not receive any compensation for their work on this manuscript. Publisher Copyright: © 2024 International Society of Nephrology |
| Peer review: | yes |
| URI: | http://hdl.handle.net/10362/175990 |
| DOI: | https://doi.org/10.1016/j.kint.2024.09.012 |
| ISSN: | 0085-2538 |
| Aparece nas colecções: | NMS - Artigos em revista internacional com arbitragem científica |
Ficheiros deste registo:
| Ficheiro | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| 1-s2.0-S0085253824007051-main.pdf | 916,4 kB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.
